Literature DB >> 25274683

Understanding and targeting alkylator resistance in glioblastoma.

Wolfgang Wick1, Michael Platten2.   

Abstract

Alkylating chemotherapy is the mainstay in the treatment of pediatric and adult glioblastoma despite primary and acquired resistance and scientific efforts to precisely define therapies for individual patients. A focus on non-MGMT-mediated temozolomide resistance for pediatric glioblastoma suggests options for new drug combinations. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25274683     DOI： 10.1158/2159-8290.CD-14-0918

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  15 in total

Review 1.  Glioblastoma vs temozolomide: can the red queen race be won?

Authors:  Anjali Arora; Kumaravel Somasundaram
Journal:  Cancer Biol Ther       Date:  2019-05-08       Impact factor: 4.742

2.  [MACF1 knockdown in glioblastoma multiforme cells increases temozolomide-induced cytotoxicity].

Authors:  Si-di Xie; Zi-Yang Chen; Hai Wang; Min-Yi He; Yun-Tao Lu; Bing-Xi Lei; He-Zhen Li; Ya-Wei Liu; Song-Tao Qi
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-09-20

3.  Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma.

Authors:  Jingwen Jiang; Lu Zhang; Haining Chen; Yunlong Lei; Tao Zhang; Yuelong Wang; Ping Jin; Jiang Lan; Li Zhou; Zhao Huang; Bowen Li; Yuan Liu; Wei Gao; Ke Xie; Liangxue Zhou; Edouard C Nice; Yong Peng; Yihai Cao; Yuquan Wei; Kui Wang; Canhua Huang
Journal:  Autophagy       Date:  2019-04-09       Impact factor: 16.016

Review 4.  Genes of the Ubiquitin Proteasome System Qualify as Differential Markers in Malignant Glioma of Astrocytic and Oligodendroglial Origin.

Authors:  Jerry Vriend; Thomas Klonisch
Journal:  Cell Mol Neurobiol       Date:  2022-07-27       Impact factor: 4.231

5.  Tumor cell network integration in glioma represents a stemness feature.

Authors:  Ruifan Xie; Tobias Kessler; Julia Grosch; Ling Hai; Varun Venkataramani; Lulu Huang; Dirk C Hoffmann; Gergely Solecki; Miriam Ratliff; Matthias Schlesner; Wolfgang Wick; Frank Winkler
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 12.300

6.  Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.

Authors:  Julie Sesen; Perrine Dahan; Sarah J Scotland; Estelle Saland; Van-Thi Dang; Anthony Lemarié; Betty M Tyler; Henry Brem; Christine Toulas; Elizabeth Cohen-Jonathan Moyal; Jean-Emmanuel Sarry; Nicolas Skuli
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

7.  Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.

Authors:  Tobias Kessler; Felix Sahm; Jonas Blaes; Matthias Osswald; Petra Rübmann; David Milford; Severino Urban; Leonie Jestaedt; Sabine Heiland; Martin Bendszus; Anne Hertenstein; Philipp-Niclas Pfenning; Carmen Ruiz de Almodóvar; Antje Wick; Frank Winkler; Andreas von Deimling; Michael Platten; Wolfgang Wick; Markus Weiler
Journal:  Oncotarget       Date:  2015-10-13

8.  Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review.

Authors:  Neha Singh; Alexandra Miner; Lauren Hennis; Sandeep Mittal
Journal:  Cancer Drug Resist       Date:  2021-03-19

9.  Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.

Authors:  Malin Wickström; Cecilia Dyberg; Jelena Milosevic; Christer Einvik; Raul Calero; Baldur Sveinbjörnsson; Emma Sandén; Anna Darabi; Peter Siesjö; Marcel Kool; Per Kogner; Ninib Baryawno; John Inge Johnsen
Journal:  Nat Commun       Date:  2015-11-25       Impact factor: 14.919

10.  Integrative analysis of TP73 profile prognostic significance in WHO grade II/III glioma.

Authors:  Yanming Chen; Ye Wang; Qiheng He; Wen Wang; Tan Zhang; Zhongyong Wang; Jun Dong; Qing Lan; Jizong Zhao
Journal:  Cancer Med       Date:  2021-06-13       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.